Show simple item record

dc.contributor.authorDiorio, C
dc.contributor.authorRobinson, PD
dc.contributor.authorAmmann, RA
dc.contributor.authorCastagnola, E
dc.contributor.authorErickson, K
dc.contributor.authorEsbenshade, A
dc.contributor.authorFisher, BT
dc.contributor.authorHaeusler, GM
dc.contributor.authorKuczynski, S
dc.contributor.authorLehrnbecher, T
dc.contributor.authorPhillips, R
dc.contributor.authorCabral, S
dc.contributor.authorDupuis, LL
dc.contributor.authorSung, L
dc.date.accessioned2020-12-09T23:52:53Z
dc.date.available2020-12-09T23:52:53Z
dc.date.issued2018-11-01
dc.identifier.citationDiorio, C., Robinson, P. D., Ammann, R. A., Castagnola, E., Erickson, K., Esbenshade, A., Fisher, B. T., Haeusler, G. M., Kuczynski, S., Lehrnbecher, T., Phillips, R., Cabral, S., Dupuis, L. L. & Sung, L. (2018). Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients. JOURNAL OF CLINICAL ONCOLOGY, 36 (31), pp.3162-+. https://doi.org/10.1200/JCO.18.00407.
dc.identifier.issn0732-183X
dc.identifier.urihttp://hdl.handle.net/11343/253351
dc.description.abstractPURPOSE: The aim of this work was to develop a clinical practice guideline for the prevention and treatment of Clostridium difficile infection (CDI) in children and adolescents with cancer and pediatric hematopoietic stem-cell transplantation (HSCT) patients. METHODS: An international multidisciplinary panel of experts in pediatric oncology and infectious diseases with patient advocate representation was convened. We performed systematic reviews of randomized controlled trials for the prevention or treatment of CDI in any population and considered the directness of the evidence to children with cancer and pediatric HSCT patients. We used the Grading of Recommendations Assessment, Development, and Evaluation approach to generate recommendations. RESULTS: The panel made strong recommendations to administer either oral metronidazole or oral vancomycin for the initial treatment of nonsevere CDI and oral vancomycin for the initial treatment of severe CDI. Fidaxomicin may be considered in the setting of recurrent CDI. The panel suggested that probiotics not be routinely used for the prevention of CDI, and that monoclonal antibodies and probiotics not be routinely used for the treatment of CDI. A strong recommendation to not use fecal microbiota transplantation was made in this population. We identified key knowledge gaps and suggested directions for future research. CONCLUSION: We present a guideline for the prevention and treatment of CDI in children and adolescents with cancer and pediatric HSCT patients. Future research should include randomized controlled trials that involve children with cancer and pediatric HSCT patients to improve the management of CDI in this population.
dc.languageEnglish
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleGuideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients
dc.typeJournal Article
dc.identifier.doi10.1200/JCO.18.00407
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.source.titleJournal of Clinical Oncology
melbourne.source.volume36
melbourne.source.issue31
melbourne.source.pages3162-+
dc.rights.licenseCC BY
melbourne.elementsid1355922
melbourne.contributor.authorHaeusler, Gabrielle
dc.identifier.eissn1527-7755
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record